Adjustable continence therapy (ACT®) balloons to treat neurogenic and non‐neurogenic female urinary incontinence. Issue 1 (11th October 2021)

• Record Type: Journal Article
• Authors: Demeestere, Amélie; de Guerry, Marie‐Liesse; Bergot, Christophe; de Hauteclocque, Astrid; Hascoet, Juliette; Gamé, Xavier; Bajeot, Anne‐Sophie; Peyronnet, Benoit; Capon, Grégoire; Perrouin‐Verbe, Marie‐Aimée; Biardeau, Xavier
• Is Part Of: Neurourology and urodynamics. Volume 41:Issue 1(2022)
• Page Start: 313
• Page End: 322
• Publication Date: 2021-10-11
• Subjects: compression device -- efficacy -- intrinsic sphincter deficiency -- safety -- stress urinary incontinence; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.24822
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract: Aims: To compare efficacy and safety between neurogenic and non‐neurogenic women after adjustable continence therapy (ACT®) balloons implantation to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency. Methods: In the present retrospective multicentric study, all neurogenic and non‐neurogenic women implanted with ACT® balloons between 2000 and 2018 were considered for inclusion. Efficacy was compared 1 year after implantation, and women were allocated in three different groups as follows. Success: maximum 1 pad per day and patient's impression of improvement assessed using a numeral rating scale (NRS) ≥8/10. Improvement: decrease of daily pad use and/or NRS ≥5/10. Failure: increase or stability of daily pad use or NRS <5/10. Overall surgical complications and explantations were compared 1 year after implantation. Results: Among the 277 included women, 51 presented with a neurologic underlying disease. Mean age at implantation was 68.5 years. There was no significant difference in efficacy between neurogenic and non‐neurogenic women with a success rate of 39.2% and 36.3%, respectively ( p = 0.69). Similarly, improvement rate was reported to be 31.4% and 33.6%, in neurogenic and non‐neurogenic women, respectively ( p = 0.92). The overall surgical complications rate (24% vs. 34.5%, p = 0.15) and the explantation rate (19.6% vs. 28.8%, p = 0.18) were not significantly different. Conclusion: ACT balloons may be proposed to treat mixed or SUI in females with ISD. Efficacy and safety profiles appear to be similar in both neurogenic and non‐neurogenic patients.